DE69637571D1 - Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen - Google Patents
Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellenInfo
- Publication number
- DE69637571D1 DE69637571D1 DE69637571T DE69637571T DE69637571D1 DE 69637571 D1 DE69637571 D1 DE 69637571D1 DE 69637571 T DE69637571 T DE 69637571T DE 69637571 T DE69637571 T DE 69637571T DE 69637571 D1 DE69637571 D1 DE 69637571D1
- Authority
- DE
- Germany
- Prior art keywords
- immune response
- presenting cells
- antigen
- reinforcing
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US572795P | 1995-10-20 | 1995-10-20 | |
PCT/US1996/016825 WO1997014426A1 (en) | 1995-10-20 | 1996-10-18 | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69637571D1 true DE69637571D1 (de) | 2008-08-07 |
Family
ID=21717413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69637571T Expired - Lifetime DE69637571D1 (de) | 1995-10-20 | 1996-10-18 | Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen |
Country Status (9)
Country | Link |
---|---|
US (5) | US6821517B1 (de) |
EP (1) | EP0859625B1 (de) |
JP (1) | JP4125784B2 (de) |
AT (1) | ATE399022T1 (de) |
AU (1) | AU703120B2 (de) |
CA (1) | CA2232344C (de) |
DE (1) | DE69637571D1 (de) |
ES (1) | ES2309992T3 (de) |
WO (1) | WO1997014426A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0859625B1 (de) * | 1995-10-20 | 2008-06-25 | University Of Nebraska Board Of Regents | Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen |
US20080286228A1 (en) * | 1995-10-20 | 2008-11-20 | Tarantolo Stefano R | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
GB9930591D0 (en) * | 1999-12-23 | 2000-02-16 | Univ London | Component for vaccine |
US20030138434A1 (en) * | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
GB0208817D0 (en) * | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
US7361742B2 (en) * | 2002-12-02 | 2008-04-22 | Resistentia Pharmaceuticals Ab | Methods and materials for treating inflammatory conditions |
US20080152648A1 (en) * | 2006-09-26 | 2008-06-26 | Alexion Pharmaceuticals, Inc. | Compositions and methods for enhancing an adjuvant |
AU2008280436A1 (en) * | 2007-07-24 | 2009-01-29 | Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre | Compositions and methods for generating an immune response in a subject |
BRPI0817209A2 (pt) * | 2007-09-20 | 2015-03-10 | David Gladstone Inst | Composições de polipeptídeo de elemento nuclear intercalado longo e métodos de uso das mesmas |
EP2250278B1 (de) * | 2008-02-21 | 2023-04-05 | Burnham Institute for Medical Research | Verfahren und zusammensetzungen in zusammenhang mit peptiden und proteinen mit c-terminalen elementen |
CA2766634A1 (en) | 2009-06-22 | 2011-01-13 | Burnham Institute For Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
FR2955773B1 (fr) | 2010-02-01 | 2017-05-26 | Commissariat A L'energie Atomique | Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination |
WO2012006149A2 (en) * | 2010-06-29 | 2012-01-12 | Board Of Regents Of The University Of Nebraska | Analogs of c5a and methods of using same |
WO2013082535A2 (en) | 2011-12-02 | 2013-06-06 | Board Of Regents Of The University Of Nebraska | Controlled-release peptide compositions and uses thereof |
AU2016228771A1 (en) | 2015-03-11 | 2017-10-26 | Board Of Regents Of The University Of Nebraska | Conformationally stable analogs of the response selective C5a agonist EP67 |
US11911464B2 (en) | 2018-09-14 | 2024-02-27 | Prommune, Inc. | Anti-parasitic immunological compositions |
CN111544585A (zh) * | 2019-02-11 | 2020-08-18 | 北京卡替医疗技术有限公司 | 一种可助推免疫细胞在体内扩增的佐剂 |
WO2023133526A2 (en) * | 2022-01-06 | 2023-07-13 | Washington University | Methods and compositions for enhancement of tumor immunogenicity and stimulating anti-tumor immune responses in an animal |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2117514B (en) * | 1982-03-29 | 1985-08-29 | East Anglian Regional Health | Polyvalent antiglobulin reagent |
JPH0788398B2 (ja) * | 1983-10-17 | 1995-09-27 | サントリー株式会社 | 新規生理活性ポリペプチドおよびその製造法 |
GB2177514B (en) | 1985-07-04 | 1988-07-06 | Isc Chemicals Ltd | Leak testing of electrical or electronic components |
GB8610983D0 (en) * | 1986-05-06 | 1986-06-11 | Connaught Lab | Enhancement of antigen immunogenicity |
DE68924850T2 (de) | 1988-06-14 | 1996-10-10 | Cell Med Inc | Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren. |
US5032401A (en) * | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5262303A (en) * | 1989-10-13 | 1993-11-16 | Trustees Of Boston University | Ligand/anti-ligand assays for adherent proteins |
US5840840A (en) * | 1990-04-17 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Selective RNase cytotoxic reagents |
US6248332B1 (en) * | 1990-10-05 | 2001-06-19 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
WO1992005793A1 (en) * | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
JPH07108232B2 (ja) * | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
GB9027767D0 (en) * | 1990-12-21 | 1991-02-13 | Cambridge Antibody Tech | Binding substances |
US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
AU671971B2 (en) * | 1991-11-29 | 1996-09-19 | Chiron Corporation | Anti-cancer immunotherapeutic vector constructs |
US5804187A (en) * | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
US5614370A (en) * | 1994-03-18 | 1997-03-25 | Merck & Co., Inc. | Assay to identify human C5a antagonists and agonists |
US5696230A (en) | 1994-08-31 | 1997-12-09 | The Board Of Regents Of The University Of Nebraska | High-affinity response-selective C-terminal analogs of C5a anaphylatoxin |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
GB9501079D0 (en) * | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
EP0859625B1 (de) * | 1995-10-20 | 2008-06-25 | University Of Nebraska Board Of Regents | Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
FR2775977B1 (fr) * | 1998-03-10 | 2000-06-23 | Oreal | Composes lipidiques derives des bases sphingoides, leur procede de preparation et leurs utilisations en cosmetique et en dermopharmacie |
US20050089524A1 (en) * | 2002-03-01 | 2005-04-28 | Sanderson Sam D. | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
-
1996
- 1996-10-18 EP EP96936768A patent/EP0859625B1/de not_active Expired - Lifetime
- 1996-10-18 JP JP51607597A patent/JP4125784B2/ja not_active Expired - Fee Related
- 1996-10-18 DE DE69637571T patent/DE69637571D1/de not_active Expired - Lifetime
- 1996-10-18 US US09/051,685 patent/US6821517B1/en not_active Expired - Fee Related
- 1996-10-18 ES ES96936768T patent/ES2309992T3/es not_active Expired - Lifetime
- 1996-10-18 CA CA002232344A patent/CA2232344C/en not_active Expired - Fee Related
- 1996-10-18 AU AU74608/96A patent/AU703120B2/en not_active Ceased
- 1996-10-18 WO PCT/US1996/016825 patent/WO1997014426A1/en active Application Filing
- 1996-10-18 AT AT96936768T patent/ATE399022T1/de active
-
2000
- 2000-05-05 US US09/566,922 patent/US7063847B1/en not_active Expired - Fee Related
-
2001
- 2001-09-17 US US09/954,349 patent/US7358087B2/en not_active Expired - Fee Related
-
2004
- 2004-05-28 US US10/856,455 patent/US7291336B2/en not_active Expired - Fee Related
-
2006
- 2006-06-13 US US11/451,739 patent/US20070031445A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2232344A1 (en) | 1997-04-24 |
US7291336B2 (en) | 2007-11-06 |
AU7460896A (en) | 1997-05-07 |
US20050025784A1 (en) | 2005-02-03 |
EP0859625B1 (de) | 2008-06-25 |
EP0859625A1 (de) | 1998-08-26 |
JPH11515005A (ja) | 1999-12-21 |
US20070031445A1 (en) | 2007-02-08 |
US6821517B1 (en) | 2004-11-23 |
US7063847B1 (en) | 2006-06-20 |
US7358087B2 (en) | 2008-04-15 |
AU703120B2 (en) | 1999-03-18 |
US20020091234A1 (en) | 2002-07-11 |
CA2232344C (en) | 2005-04-05 |
ES2309992T3 (es) | 2008-12-16 |
WO1997014426A1 (en) | 1997-04-24 |
JP4125784B2 (ja) | 2008-07-30 |
EP0859625A4 (de) | 2004-03-03 |
ATE399022T1 (de) | 2008-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69637571D1 (de) | Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen | |
DE69534946D1 (de) | Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren | |
DE69636891D1 (de) | Immunstimulierende zusammensetzung und verfahren | |
ATE456378T1 (de) | Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen | |
TR200000224T2 (tr) | Nükleotid analog kompozisyonlar. | |
IL141021A (en) | Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases | |
DE69531741D1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe | |
IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
ATE196314T1 (de) | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit | |
PL325373A1 (en) | Compounds and methods useful in tuberculosos immunotherapy and diagnostics | |
IL138424A (en) | Covalently reactive antigen analogs and pharmaceutical compositions containing the same | |
JPS6317699A (ja) | ヒトγ−インタ−フエロン特異的受容体蛋白質およびそれに対する抗体 | |
EE200000039A (et) | MHC II klassi ligandi kasutamine, farmatseutiline kompositsioon, transfekteeritud kasvajarakud, transfekteeritud rakkude ja kasvajarakkude valmistamismeetod ning nende kasutamine | |
DE69839273D1 (de) | Krebs immuntherapie mit semi-allogenen zellen | |
DE69620271T2 (de) | Polyribosylribitol-phosphat enthaltende Haemophilus-influenzae-Typ-b-Impfstoffzubereitung und Verfahren zur deren Herstellung | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
Nakashima et al. | Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models | |
IS4922A (is) | Fjölpeptíð sem geta myndað formgerðir mótefnisvakabindinga með sérvirkni fyrir resus D mótefnisvaka, DNA-ið sem táknar þau og aðferðin til að búa þautil og notkun | |
WO1997005899A3 (en) | Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same | |
BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
AU9363398A (en) | Hepatitis c receptor protein cd81 | |
EP1820514A3 (de) | Therapeutische Zusammensetzungen, die durch Wechseln des Antigens eine Immunantwort produzieren | |
ATE226065T1 (de) | Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung | |
Fenton et al. | A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma | |
DE69928523D1 (de) | Verotoxin b untereinheit zur immunisierunug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |